[go: up one dir, main page]

AR076284A1 - Inmunoconjugados de antimesotelina y usos de los mismos - Google Patents

Inmunoconjugados de antimesotelina y usos de los mismos

Info

Publication number
AR076284A1
AR076284A1 ARP100101232A ARP100101232A AR076284A1 AR 076284 A1 AR076284 A1 AR 076284A1 AR P100101232 A ARP100101232 A AR P100101232A AR P100101232 A ARP100101232 A AR P100101232A AR 076284 A1 AR076284 A1 AR 076284A1
Authority
AR
Argentina
Prior art keywords
antibodies
tumors
antigen binding
immunoconjugates
binding regions
Prior art date
Application number
ARP100101232A
Other languages
English (en)
Inventor
Antje Kahnert
Kerstin Berhorster
Iring Heisler
Charlotte Kopitz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR076284A1 publication Critical patent/AR076284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Inmunoconjugados compuestos por anticuerpos, por ejemplo anticuerpos monoclonales, o fragmentos de anticuerpos, que se unen a la mesotelina, que están conjugados con agentes citotoxicos, por ejemplo maitansina, o sus derivados, y/o se co-administran o formulan con uno o más agentes anticancerosos adicionales. Los inmunoconjugados se pueden usar para tratar y/o diagnosticar y/o monitorizar cánceres, por ejemplo regiones de union al antígeno recombinantes de tumores solidos y anticuerpos y fragmentos funcionales que contienen dichas regiones de union al antígeno que son específicas del polipéptido de mesotelina de 40 kDa anclado a la membrana, que se sobreexpresa en varios tumores, tales como tumores pancreáticos y ováricos, mesotelioma y células de cáncer de pulmon.
ARP100101232A 2009-04-29 2010-04-13 Inmunoconjugados de antimesotelina y usos de los mismos AR076284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09005909 2009-04-29

Publications (1)

Publication Number Publication Date
AR076284A1 true AR076284A1 (es) 2011-06-01

Family

ID=42332769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101232A AR076284A1 (es) 2009-04-29 2010-04-13 Inmunoconjugados de antimesotelina y usos de los mismos

Country Status (41)

Country Link
US (5) US9084829B2 (es)
EP (2) EP3292874B1 (es)
JP (3) JP5616433B2 (es)
KR (1) KR101681795B1 (es)
CN (2) CN106177984B (es)
AR (1) AR076284A1 (es)
AU (1) AU2010243942B2 (es)
BR (1) BRPI1014637B1 (es)
CA (1) CA2760114C (es)
CL (1) CL2011002681A1 (es)
CO (1) CO6450601A2 (es)
CR (1) CR20110566A (es)
CU (1) CU23929B1 (es)
CY (2) CY1119738T1 (es)
DK (2) DK2424569T3 (es)
DO (1) DOP2011000331A (es)
EC (1) ECSP11011423A (es)
ES (2) ES2790732T3 (es)
GT (1) GT201100269A (es)
HN (1) HN2011002834A (es)
HR (2) HRP20180015T1 (es)
HU (2) HUE037853T2 (es)
IL (1) IL215769A (es)
JO (1) JO3486B1 (es)
LT (2) LT2424569T (es)
MA (1) MA33229B1 (es)
MX (1) MX2011011365A (es)
MY (1) MY158624A (es)
NO (1) NO2424569T3 (es)
NZ (1) NZ596013A (es)
PE (1) PE20120556A1 (es)
PL (2) PL3292874T3 (es)
PT (2) PT3292874T (es)
SG (1) SG175254A1 (es)
SI (2) SI3292874T1 (es)
TN (1) TN2011000547A1 (es)
TW (2) TWI472343B (es)
UA (2) UA106492C2 (es)
UY (1) UY32560A (es)
WO (1) WO2010124797A1 (es)
ZA (1) ZA201107757B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ610976A (en) 2010-12-20 2015-07-31 Genentech Inc Anti-mesothelin antibodies and immunoconjugates
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
MX339927B (es) 2011-03-29 2016-06-16 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
EP3327037B1 (en) 2012-08-21 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014043523A1 (en) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing
CN104955845B (zh) * 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
DK3060256T3 (da) * 2013-10-25 2019-07-29 Bayer Pharma AG Hidtil ukendt stabil formulering
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015200773A1 (en) * 2014-06-27 2015-12-30 Oregon Health & Science University Compounds that bind dystroglycan and uses thereof
EP4218724A3 (en) * 2014-08-29 2023-08-16 Corium Pharma Solutions, Inc. Microstructure array for delivery of active agents
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
HK1251948A1 (en) 2015-08-21 2019-05-03 克莱格医学有限公司 Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
CN114716557A (zh) 2016-02-03 2022-07-08 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
US20210299265A1 (en) 2016-02-05 2021-09-30 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
KR101966362B1 (ko) 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药（烟台）有限公司 一种抗间皮素抗体及其抗体药物缀合物
CN112368015B (zh) * 2018-06-18 2025-04-29 安维达生物科技公司 细胞因子融合蛋白及其用途
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
US20250154201A1 (en) * 2022-02-10 2025-05-15 Kyungpook National University Industry-Academic Cooperation Foundation Peptide binding to mesothelin, and use thereof
KR20230121560A (ko) 2022-02-10 2023-08-18 경북대학교 산학협력단 메소세린에 결합하는 펩타이드 및 이의 용도
WO2024027708A1 (zh) 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1437180A (en) 1920-12-16 1922-11-28 Wahl Co Mechanical pencil
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5773280A (en) 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
US5407653A (en) 1991-06-26 1995-04-18 Brigham And Women's Hospital Evaluation of the multidrug resistance phenotype
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
JPH0699141A (ja) * 1992-09-21 1994-04-12 Kubota Corp 石抜装置
JPH06124641A (ja) * 1992-10-08 1994-05-06 Mitsubishi Electric Corp 回路遮断器
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
JPH0945957A (ja) * 1995-07-28 1997-02-14 Oki Electric Ind Co Ltd 端面発光型ｌｅｄアレイの製造方法及びその検査方法
JP3724015B2 (ja) * 1995-08-08 2005-12-07 コベルコ建機株式会社 パイロット切換弁の応答性可変装置
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ES2212071T3 (es) 1996-01-05 2004-07-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Antigeno de mesotelio y kits para marcarlo como diana.
US7375183B1 (en) * 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
ZA9810210B (en) 1997-11-10 1999-07-14 Searle & Co Use of alkylated iminosugars to treat multidrug resistance.
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
AU760120B2 (en) * 1997-12-01 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
DE60028361T2 (de) 1999-02-26 2007-05-10 Pacific Northwest Research Institute, Seattle Verfahren und zusammensetzungen zur karzinomdiagnose
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
WO2001039744A2 (en) 1999-11-30 2001-06-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Radiation sensitive liposomes
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP1539239A4 (en) 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
KR101441358B1 (ko) 2003-05-14 2014-09-24 이뮤노젠 아이엔씨 약물 콘쥬게이트 조성물
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
EP1853322B1 (en) * 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
ES2386367T3 (es) * 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
CA2607305A1 (en) * 2005-05-12 2006-11-23 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
BRPI0610796B8 (pt) 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
US20070014720A1 (en) 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
BRPI0613783A2 (pt) * 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
PL1948180T3 (pl) * 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101951946B (zh) * 2007-10-01 2014-12-10 百时美施贵宝公司 结合间皮素的人抗体及其应用
MY157164A (en) 2007-11-26 2016-05-13 Bayer Ip Gmbh Anti-mesothelin antibodies and uses thereof
KR20210005318A (ko) * 2008-04-30 2021-01-13 이뮤노젠 아이엔씨 가교제 및 그 용도
US20090298088A1 (en) * 2008-05-30 2009-12-03 Belyaev Alexander S Cleavable catalytic binding and detection system
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
SG10201405377XA (en) * 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
JP2012519712A (ja) 2009-03-06 2012-08-30 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体製剤
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
SG176068A1 (en) * 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
AR086364A1 (es) 2011-04-21 2013-12-11 Bayer Ip Gmbh Conjugados de principio activo-ligante (adc) y el uso de los mismos
DK3060256T3 (da) 2013-10-25 2019-07-29 Bayer Pharma AG Hidtil ukendt stabil formulering

Also Published As

Publication number Publication date
JP2017039735A (ja) 2017-02-23
WO2010124797A8 (en) 2011-12-08
EP2424569A1 (en) 2012-03-07
TWI472343B (zh) 2015-02-11
HRP20200884T1 (hr) 2020-09-04
UY32560A (es) 2010-11-30
SG175254A1 (en) 2011-11-28
IL215769A0 (en) 2012-01-31
MX2011011365A (es) 2012-09-28
AU2010243942A1 (en) 2011-11-10
US10781263B2 (en) 2020-09-22
NO2424569T3 (es) 2018-03-17
BRPI1014637B1 (pt) 2021-08-24
JO3486B1 (ar) 2020-07-05
HUE037853T2 (hu) 2018-09-28
WO2010124797A1 (en) 2010-11-04
AU2010243942B2 (en) 2015-01-29
CU20110200A7 (es) 2012-06-21
CN102458477A (zh) 2012-05-16
PL3292874T3 (pl) 2020-10-19
DOP2011000331A (es) 2011-11-15
PT2424569T (pt) 2018-01-11
US20180201690A1 (en) 2018-07-19
LT2424569T (lt) 2018-02-12
CA2760114A1 (en) 2010-11-04
ECSP11011423A (es) 2011-11-30
HRP20180015T1 (hr) 2018-02-09
DK2424569T3 (en) 2018-01-15
MY158624A (en) 2016-10-31
KR101681795B1 (ko) 2016-12-01
CA2760114C (en) 2017-11-21
BRPI1014637A2 (pt) 2019-04-16
EP3292874B1 (en) 2020-04-08
PE20120556A1 (es) 2012-05-09
ES2790732T3 (es) 2020-10-29
PT3292874T (pt) 2020-05-15
HN2011002834A (es) 2013-10-28
SI2424569T1 (en) 2018-02-28
US20150322160A1 (en) 2015-11-12
US20170327589A1 (en) 2017-11-16
UA116874C2 (uk) 2018-05-25
US20200377614A1 (en) 2020-12-03
ZA201107757B (en) 2012-12-27
HUE049795T2 (hu) 2020-10-28
TW201105351A (en) 2011-02-16
JP5616433B2 (ja) 2014-10-29
EP3292874A1 (en) 2018-03-14
NZ596013A (en) 2013-11-29
RU2011148220A (ru) 2013-06-10
JP2015042174A (ja) 2015-03-05
IL215769A (en) 2016-12-29
GT201100269A (es) 2013-08-21
CU23929B1 (es) 2013-07-31
CY1119738T1 (el) 2018-06-27
US9084829B2 (en) 2015-07-21
JP6395783B2 (ja) 2018-09-26
CN106177984B (zh) 2019-12-24
CY1123165T1 (el) 2021-10-29
ES2655273T3 (es) 2018-02-19
AU2010243942A8 (en) 2012-06-07
CN102458477B (zh) 2016-08-24
JP2012525342A (ja) 2012-10-22
SI3292874T1 (sl) 2020-07-31
LT3292874T (lt) 2020-06-10
CO6450601A2 (es) 2012-05-31
EP2424569B1 (en) 2017-10-18
US10647779B2 (en) 2020-05-12
TN2011000547A1 (en) 2013-05-24
CL2011002681A1 (es) 2012-07-13
KR20120031265A (ko) 2012-04-02
UA106492C2 (uk) 2014-09-10
US20120189644A1 (en) 2012-07-26
MA33229B1 (fr) 2012-04-02
HK1170671A1 (zh) 2013-03-08
PL2424569T3 (pl) 2018-03-30
TW201529084A (zh) 2015-08-01
CN106177984A (zh) 2016-12-07
DK3292874T3 (da) 2020-06-02
CR20110566A (es) 2012-02-20

Similar Documents

Publication Publication Date Title
AR076284A1 (es) Inmunoconjugados de antimesotelina y usos de los mismos
CR11456A (es) Anticuerpos antimesotelina y usos de los mismos
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
CO6690769A2 (es) Proteínas de unión a antígenos que se unen al receptor her3, polinucleótidos que los comdifican y composiciones que los contienen, útiles a el tratamiento o profilaxis de varios tipos de cancer
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
ECSP19072235A (es) Anticuerpos anti-ILT4 y fragmentos de unión a antígeno
CO2017010190A2 (es) Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19
BR112019006781A2 (pt) receptores de antígeno quiméricos para o tratamento de câncer
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
EA201891966A1 (ru) Молекулы, связывающие bcma, и способы их применения
CR20170079A (es) Agentes de unión a cd123 y usos de estos
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
PE20090245A1 (es) Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
ECSP12011757A (es) Anticuerpos que se unen específicamente al receptor epha2
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
MX2020004220A (es) Anticuerpos anti-glico-muc1 y sus usos.
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos
AR106284A1 (es) Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19
DOP2012000083A (es) Anticuerpos que se unen especificamente al receptor epha2
DOP2009000055A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cancer

Legal Events

Date Code Title Description
FG Grant, registration